PTCT
Price
$66.09
Change
+$0.03 (+0.05%)
Updated
Oct 14 closing price
Capitalization
5.25B
8 days until earnings call
Intraday Buy/Sell Signals
XNCR
Price
$12.43
Change
-$1.53 (-10.96%)
Updated
Oct 14 closing price
Capitalization
885.83M
26 days until earnings call
Intraday Buy/Sell Signals
Interact to see
Advertisement

PTCT vs XNCR

Header iconPTCT vs XNCR Comparison
Open Charts PTCT vs XNCRBanner chart's image
PTC Therapeutics
Price$66.09
Change+$0.03 (+0.05%)
Volume$954.49K
Capitalization5.25B
Xencor
Price$12.43
Change-$1.53 (-10.96%)
Volume$2.9M
Capitalization885.83M
PTCT vs XNCR Comparison Chart in %
PTCT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XNCR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
PTCT vs. XNCR commentary
Oct 16, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is PTCT is a Hold and XNCR is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Oct 16, 2025
Stock price -- (PTCT: $66.09 vs. XNCR: $12.42)
Brand notoriety: PTCT and XNCR are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: PTCT: 72% vs. XNCR: 279%
Market capitalization -- PTCT: $5.25B vs. XNCR: $885.83M
PTCT [@Biotechnology] is valued at $5.25B. XNCR’s [@Biotechnology] market capitalization is $885.83M. The market cap for tickers in the [@Biotechnology] industry ranges from $105.69B to $0. The average market capitalization across the [@Biotechnology] industry is $2.02B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

PTCT’s FA Score shows that 1 FA rating(s) are green whileXNCR’s FA Score has 1 green FA rating(s).

  • PTCT’s FA Score: 1 green, 4 red.
  • XNCR’s FA Score: 1 green, 4 red.
According to our system of comparison, both PTCT and XNCR are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

PTCT’s TA Score shows that 4 TA indicator(s) are bullish while XNCR’s TA Score has 3 bullish TA indicator(s).

  • PTCT’s TA Score: 4 bullish, 4 bearish.
  • XNCR’s TA Score: 3 bullish, 4 bearish.
According to our system of comparison, PTCT is a better buy in the short-term than XNCR.

Price Growth

PTCT (@Biotechnology) experienced а +3.42% price change this week, while XNCR (@Biotechnology) price change was +3.24% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.44%. For the same industry, the average monthly price growth was +17.42%, and the average quarterly price growth was +81.94%.

Reported Earning Dates

PTCT is expected to report earnings on Oct 23, 2025.

XNCR is expected to report earnings on Nov 10, 2025.

Industries' Descriptions

@Biotechnology (+0.44% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
PTCT($5.25B) has a higher market cap than XNCR($886M). PTCT YTD gains are higher at: 46.411 vs. XNCR (-45.909). PTCT has higher annual earnings (EBITDA): 841M vs. XNCR (-125.38M). PTCT has more cash in the bank: 1.99B vs. XNCR (444M). XNCR has less debt than PTCT: XNCR (67.9M) vs PTCT (388M). PTCT has higher revenues than XNCR: PTCT (1.77B) vs XNCR (147M).
PTCTXNCRPTCT / XNCR
Capitalization5.25B886M593%
EBITDA841M-125.38M-671%
Gain YTD46.411-45.909-101%
P/E Ratio9.37N/A-
Revenue1.77B147M1,201%
Total Cash1.99B444M448%
Total Debt388M67.9M571%
FUNDAMENTALS RATINGS
PTCT vs XNCR: Fundamental Ratings
PTCT
XNCR
OUTLOOK RATING
1..100
2226
VALUATION
overvalued / fair valued / undervalued
1..100
99
Overvalued
85
Overvalued
PROFIT vs RISK RATING
1..100
73100
SMR RATING
1..100
10097
PRICE GROWTH RATING
1..100
3940
P/E GROWTH RATING
1..100
115
SEASONALITY SCORE
1..100
5075

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

XNCR's Valuation (85) in the Biotechnology industry is in the same range as PTCT (99). This means that XNCR’s stock grew similarly to PTCT’s over the last 12 months.

PTCT's Profit vs Risk Rating (73) in the Biotechnology industry is in the same range as XNCR (100). This means that PTCT’s stock grew similarly to XNCR’s over the last 12 months.

XNCR's SMR Rating (97) in the Biotechnology industry is in the same range as PTCT (100). This means that XNCR’s stock grew similarly to PTCT’s over the last 12 months.

PTCT's Price Growth Rating (39) in the Biotechnology industry is in the same range as XNCR (40). This means that PTCT’s stock grew similarly to XNCR’s over the last 12 months.

XNCR's P/E Growth Rating (5) in the Biotechnology industry is in the same range as PTCT (11). This means that XNCR’s stock grew similarly to PTCT’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
PTCTXNCR
RSI
ODDS (%)
Bearish Trend 8 days ago
89%
Bearish Trend 8 days ago
79%
Stochastic
ODDS (%)
Bearish Trend 8 days ago
85%
Bearish Trend 8 days ago
84%
Momentum
ODDS (%)
Bullish Trend 8 days ago
67%
N/A
MACD
ODDS (%)
Bullish Trend 8 days ago
72%
N/A
TrendWeek
ODDS (%)
Bullish Trend 8 days ago
76%
Bullish Trend 8 days ago
74%
TrendMonth
ODDS (%)
Bullish Trend 8 days ago
75%
Bullish Trend 8 days ago
72%
Advances
ODDS (%)
Bullish Trend 13 days ago
75%
Bullish Trend 8 days ago
71%
Declines
ODDS (%)
Bearish Trend 9 days ago
81%
Bearish Trend 13 days ago
82%
BollingerBands
ODDS (%)
Bearish Trend 8 days ago
86%
Bearish Trend 8 days ago
74%
Aroon
ODDS (%)
Bullish Trend 8 days ago
78%
Bullish Trend 8 days ago
61%
View a ticker or compare two or three
Interact to see
Advertisement
PTCT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XNCR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
STMSX24.400.30
+1.24%
SEI Tax-Managed Small/Mid Cap F (SIMT)
CRVRX7.980.09
+1.14%
NYLI CBRE Real Estate Fund Investor Cl
AISHX6.030.06
+1.01%
Aristotle Small/Mid Cap Equity C
NRACX50.640.08
+0.16%
Neuberger Berman Quality Equity C
FSSKX90.11N/A
N/A
Fidelity Stock Selec-Class K

PTCT and

Correlation & Price change

A.I.dvisor indicates that over the last year, PTCT has been loosely correlated with ACLX. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if PTCT jumps, then ACLX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PTCT
1D Price
Change %
PTCT100%
+0.05%
ACLX - PTCT
49%
Loosely correlated
+1.28%
IMVT - PTCT
43%
Loosely correlated
+0.81%
BHVN - PTCT
42%
Loosely correlated
+8.89%
SYRE - PTCT
42%
Loosely correlated
+11.02%
XNCR - PTCT
42%
Loosely correlated
-10.96%
More

XNCR and

Correlation & Price change

A.I.dvisor indicates that over the last year, XNCR has been loosely correlated with CRNX. These tickers have moved in lockstep 62% of the time. This A.I.-generated data suggests there is some statistical probability that if XNCR jumps, then CRNX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To XNCR
1D Price
Change %
XNCR100%
-10.96%
CRNX - XNCR
62%
Loosely correlated
-0.86%
DYN - XNCR
58%
Loosely correlated
+10.12%
NUVL - XNCR
56%
Loosely correlated
-5.67%
SYRE - XNCR
56%
Loosely correlated
+11.02%
ERAS - XNCR
56%
Loosely correlated
+0.42%
More